Cargando…
In vivo microevolution of Mycobacterium tuberculosis and transient emergence of atpE_Ala63Pro mutation during treatment in a pre-XDR TB patient
This letter describes microevolution of a pre-XDR MTB strain isolated from a pulmonary TB patient over an 18-month exposure to BDQ. MDR-TB therapies with BDQ require a functional background regimen to prevent emergence of additional resistance. https://bit.ly/3D05qT9
Autores principales: | Ghodousi, Arash, Hussain Rizvi, Alamdar, Khanzada, Faisal Masood, Akhtar, Nasim, Ghafoor, Abdul, Trovato, Alberto, Cirillo, Daniela Maria, Tahseen, Sabira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943273/ https://www.ncbi.nlm.nih.gov/pubmed/34795042 http://dx.doi.org/10.1183/13993003.02102-2021 |
Ejemplares similares
-
Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use
por: Hafkin, Jeffrey, et al.
Publicado: (2017) -
First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB
por: Lewis, Joseph M., et al.
Publicado: (2016) -
Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan
por: Ghodousi, Arash, et al.
Publicado: (2019) -
QIAreach QuantiFERON-TB for the diagnosis of Mycobacterium tuberculosis infection
por: Saluzzo, Francesca, et al.
Publicado: (2022) -
The (in)significance of TB and COVID-19 co-infection
por: Khurana, Alkesh Kumar, et al.
Publicado: (2020)